REG - GENinCode PLC - Collaboration with Sohin Genetics

GenincodeAnnouncement

17/12/2025 07:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251217:nRSQ9176La&default-theme=true

RNS Number : 9176L  GENinCode PLC  17 December 2025

17 December 2025

GENinCode Plc

("GENinCode" or the "Company")

CARDIO inCode-Score® distribution with Sohin Genetics, Mexico

Commercial agreement to distribute CARDIO inCode-Score®

for the genetic risk prediction and prevention of coronary heart disease

 

GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company
focused on the prevention of cardiovascular disease ("CVD") and risk
assessment of ovarian cancer, announces today a collaboration with Sohin
Genetics, Mexico to distribute the CARDIO inCode-Score® Polygenic Risk Score
("PRS") test for the prevention of coronary heart disease ("CHD" or "heart
disease").

 

This announcement follows the recent collaboration between GENinCode and
"AMPAC" (Mexican Association for the prevention of Atherosclerosis) dedicated
to research, education and promotion of healthy lifetstyles to combat
atherosclerosis and heart disease in Mexico.

 

Sohin Genetics provide integrated healthcare services, especially in
diagnostics, to deliver precision medicine access across their network of
hospitals and clinics. Sohin Genetics will commercially promote and market
CARDIO inCode-Score in the Mexican market including training, sample handling
and ordering via the GENinCode 'SITAB' international reporting system. Mexico
has a population of over 130 million with an estimated cardiovascular disease
market of USD$ 4.3 billion with coronary heart disease the leading cause of
death.

 

CARDIO inCode-Score® (PRS)

CARDIO inCode-Score is a clinically validated, commercially available
polygenic risk score (PRS) based on DNA extracted from a simple saliva or
blood sample. The extracted DNA is scored to identify an individual's
inherited genetic risk of heart disease thereby enabling prevention through
lifestyle change and/or therapeutic treatment. The test has been designed and
optimized for population-based risk prediction and primary prevention of heart
disease and is being made available at affordable pricing to international
healthcare systems.

 

By integrating CARDIO inCode-Score® into existing clinical pathways,
healthcare providers can more accurately identify individuals at heightened
'lifetime risk' of heart disease and personalise treatment and prevention
strategies. This preventive approach reduces the incidence of severe
cardiovascular events, such as heart attacks and strokes, and mitigates the
economic costs associated with long-term heart disease care. It represents a
significant step to improving public health outcomes and particularly in
addressing the global burden of cardiovascular disease.

 

Matthew Walls, GENinCode Chief Executive Officer said; "We are delighted to
announce this latest distribution agreement with Sohin Genetics to sell CARDIO
inCode-Score in Mexico. The collaboration will extend our reach into this
growing cardiovascular disease market and allow us to consider other tests for
distribution in the region."

 

For more information visit www.genincode.com (http://www.genincode.com)

 

Enquiries:

 GENinCode Plc                               www.genincode.com
                 (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Cavendish Capital Markets Limited                                  Tel: +44 (0)20 7397 8900
 Giles Balleny (Corporate Finance)
 Nigel Birks (Life Sciences Specialist Sales)
 Harriet Ward (Corporate Broking)
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited
 Anna Dunphy / Marcus Ulker       Tel: 020 7933 8780 or genincode@walbrookpr.com
                                  (mailto:genincode@walbrookpr.com)

 

 

Notes for editors

 

 

Coronary Heart Disease

Coronary Heart Disease ("CHD"), is the leading cause of death globally and is
responsible for approx. 9 million deaths annually and estimated to affect over
250 million people suffering with symptoms of CHD(1). In the UK, it is the
most common form of death and disability, with approximately 2.3 million
people living with the condition(2).

 

CHD occurs when the coronary arteries, which supply blood to the heart, become
narrowed by build-up of fatty materials (cholesterol and other lipids) which
give rise to what is commonly known as atherosclerosis or heart disease.
Atherosclerosis restricts blood flow to the heart causing symptoms like angina
(chest pain) with increasing atherosclerosis burden giving rise to heart
attack (or ischemic stroke) if the artery becomes completely blocked by a
blood clot.

 

(1. ) World Health Organisation - www.who.int (http://www.who.int) - The
leading causes of death

(2. ) British Heart Foundation - www.bhf.org.uk (http://www.bhf.org.uk) -
Statistics

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGRBDDXDBDGUR



            Copyright 2019 Regulatory News Service, all rights reserved